Lung cancer is the most common cancer worldwide & lung biopsy is the gold standard method of diagnosis
Early diagnosis has been proven to save lives making lung biopsy a vital armament in the battle against lung cancer
Unfortunately, 1 in 3 patients undergoing a lung biopsy suffer from a collapsed lung, known as pneumothorax
This dangerous complication converts a routine outpatient procedure to one requiring hospitilisation, for up to a week, for invasive treatment & follow-up
This results in healthcare costs in excess of $15,000 per patient making it the No. 1 hospital cost & complication post lung biopsy
Selio Medical adopts a unique approach by preventing the pneumothorax occurring before the biopsy even takes place.
The Selio System™ is a single use, prophylactic device, comprising a smart delivery needle together with a biodegradable hydrogel sealant.
Our proven technology seamlessly integrates with the current standard of care and enables the clinician to pre-seal the access route into the lung before the biopsy.
The Selio System™ allows the patient to safely return home on the same day as their procedure. This significantly improves the patient’s quality of care while preventing further treatment and costs.
Selio Medical, Headstart/Proof-of-Concept Winner 2017 : EIT Health UK-Ireland @ Oxford University. Read more
Selio Medical, Winner at Medtech Innovator Finals San Jose out of over 600 medical device start-up companies. Read more
Selio Medical highlighted as one of 5 Irish big ideas that can transform medical treatment. Read more
Selio Medical selected as first international company to take part in prestigious National Science Foundation icorps accelerator program. Completed in Gerogia Tech, Atlanta 2017. Read more
2019 Selio European Consortium awarded multimillion Euro grant from EIT Health to support device development and regulatory submissions.
August 2020: Selio Medical delighted to welcome Tanaiste Leo Varadkar and Enterprise Ireland CEO Julie Sinnamon, to the new Selio Medical facility in the Guinness Enterprise Centre.
August 2021: Selio Medical very proud to welcome a large delegation as part of President Macron visit to Ireland. This delegation included a number of dignitaries including French Finance Minister Bruno Le Maire and Irish Minister for Finance Paschal Donohoe.
August 2021. Selio Medical delighted to welcome new CEO of Enterprise Ireland Leo Clancy and Chairman of GEC, David Varian to our facility.
November 2021: Selio Medical proud to be included in the Sunday Business Post list of 2021 ‘Hot 100 Start-ups’.
25 November 2021: Delighted to receive the prestigious Rising Star Award at the Ireland-France Business Awards presented by An Taoiseach Micheal Martin and French Minister Franck Riester
Co-founders Dr Garrett Ryan and Colm McGarvey identified this large unmet clinical need during the Bioinnovate Fellowship Programme. Subsequently, the technology was optimised and de-risked at Trinity College Dublin largely supported by grant funding from Enterprise Ireland. Selio Medical is currently based in Dublin, Ireland.
Dr. Garrett Ryan
An honest and results focused engineer with extensive experience in the development and commercialisation of medical devices. He has led multiple medical devices from concept to market in the cardiovascular, endo-surgery, urological and respiratory fields. Garrett completed both his undergraduate and PhD training at National University of Ireland, Galway.
An ambitious, dynamic and visionary professional with over 22 years commercial experience, national and international, within the medical device and pharmacy sectors. Colm holds a BSc Degree in Pharmacy from Queens University Belfast and a MSc in Bio-Innovation from University College Cork.